Inva has activist Alex Denner in control of the board(5/5) and management which has been cut down to 2 people, includes CEO who is also Sarissa Executive. GSK has 30% ownership and probably will be likely buyer, they must have been waiting on Asthma indication approval which came earlier this month.
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。